Two doses of a simple tuberculosis vaccine after surgery support the immune system in fighting cancer cells and could significantly improve treatment outcomes for the most common form of bladder cancer, according to a pilot study involving 40 patients. Initial results of the RUTIVAC-1 study were presented at EAU25.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Diarrhea in children
The problem of parental expectations
- From symptom to diagnosis
Multilocular cystic renal cell carcinoma (MCRCC)
- Shaping the Future with LLM & Co.
AI in Everyday Clinical Practice: Friend or Foe?
- Ulcerative colitis: current evidence on anti-inflammatory therapies
Remission induction and maintenance with biologics and JAK-i
- Bronchiectasis
New strategies against neutrophilic inflammation
- IBD in childhood
Pneumococcal vaccination without negative consequences
- Seborrheic Dermatitis in Adults and Adolescents
Current State of Knowledge and New Therapeutic Approaches
- Plastic surgery and reconstructive microsurgery for DFS